ATE333503T1 - Synthetische gene für gagpol und deren verwendungen - Google Patents

Synthetische gene für gagpol und deren verwendungen

Info

Publication number
ATE333503T1
ATE333503T1 AT01960229T AT01960229T ATE333503T1 AT E333503 T1 ATE333503 T1 AT E333503T1 AT 01960229 T AT01960229 T AT 01960229T AT 01960229 T AT01960229 T AT 01960229T AT E333503 T1 ATE333503 T1 AT E333503T1
Authority
AT
Austria
Prior art keywords
gagpol
synthetic genes
generation
synthetic gag
gagpol genes
Prior art date
Application number
AT01960229T
Other languages
English (en)
Inventor
Ralf Wagner
Markus Graf
Ludwig Deml
Kurt Bieler
Original Assignee
Geneart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE333503(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geneart Ag filed Critical Geneart Ag
Application granted granted Critical
Publication of ATE333503T1 publication Critical patent/ATE333503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01960229T 2000-05-18 2001-05-18 Synthetische gene für gagpol und deren verwendungen ATE333503T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110623A EP1156112B1 (de) 2000-05-18 2000-05-18 Synthetische Gene für gagpol und deren Verwendungen

Publications (1)

Publication Number Publication Date
ATE333503T1 true ATE333503T1 (de) 2006-08-15

Family

ID=8168767

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00110623T ATE318908T1 (de) 2000-05-18 2000-05-18 Synthetische gene für gagpol und deren verwendungen
AT01960229T ATE333503T1 (de) 2000-05-18 2001-05-18 Synthetische gene für gagpol und deren verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00110623T ATE318908T1 (de) 2000-05-18 2000-05-18 Synthetische gene für gagpol und deren verwendungen

Country Status (10)

Country Link
US (3) US7378515B2 (de)
EP (2) EP1156112B1 (de)
CN (1) CN1429270A (de)
AT (2) ATE318908T1 (de)
AU (1) AU2001281781A1 (de)
BR (1) BR0110706A (de)
CA (1) CA2408433A1 (de)
DE (2) DE60026199T2 (de)
HK (2) HK1042319B (de)
WO (1) WO2001088141A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EP1201750A1 (de) 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
US20070015721A1 (en) * 2001-09-20 2007-01-18 Andrew Beaton Hiv-gag codon-optimised dna vaccines
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
ES2429338T3 (es) 2002-12-23 2013-11-14 Vical Incorporated Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano
US20050220816A1 (en) * 2004-03-31 2005-10-06 Advanced Bioscience Laboratories, Inc. Mutant viral nucleic acids and vaccine containing same
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
MX2007001292A (es) * 2004-08-03 2007-07-04 Geneart Ag Metodo para modular la expresion genica al alterar el contendido de cpg.
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
EP2839011B1 (de) 2012-04-17 2016-09-14 F. Hoffmann-La Roche AG Verfahren zur expression von polypeptiden mittels modifizierter nucleinsäuren
MX2021015193A (es) 2019-06-28 2022-01-18 Hoffmann La Roche Metodo para la produccion de un anticuerpo.
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342916T1 (de) * 1997-02-07 2006-11-15 Merck & Co Inc Synthetische hiv gag gene
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用

Also Published As

Publication number Publication date
EP1156112B1 (de) 2006-03-01
EP1282712B1 (de) 2006-07-19
DE60026199T2 (de) 2006-11-23
WO2001088141A2 (en) 2001-11-22
DE60121572D1 (de) 2006-08-31
AU2001281781A1 (en) 2001-11-26
EP1282712A2 (de) 2003-02-12
DE60121572T2 (de) 2007-06-28
US8287881B2 (en) 2012-10-16
DE60026199D1 (de) 2006-04-27
BR0110706A (pt) 2003-01-28
WO2001088141A3 (en) 2002-04-18
US20070293448A1 (en) 2007-12-20
HK1042319A1 (en) 2002-08-09
CA2408433A1 (en) 2001-11-22
ATE318908T1 (de) 2006-03-15
US20040152069A1 (en) 2004-08-05
CN1429270A (zh) 2003-07-09
US20130122585A1 (en) 2013-05-16
US7378515B2 (en) 2008-05-27
EP1156112A1 (de) 2001-11-21
HK1053853A1 (en) 2003-11-07
HK1042319B (zh) 2006-10-20

Similar Documents

Publication Publication Date Title
ATE333503T1 (de) Synthetische gene für gagpol und deren verwendungen
ATE361366T1 (de) Aus bacillus stammende transglutaminase
MXPA03000634A (es) Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
ME00326B (me) Anti-il-12-antitjela, kompozicije, metode i njihove upotrebe
IL143326A0 (en) Method of cloning porcine animals
HRP20030088B1 (hr) Anti-dvostruka integrinska protutijela, pripravci, postupci i primjena
EP1555325A4 (de) Neue fructosylpeptidoxidase und deren nutzung
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
EP0752874A4 (de) Ein verstärkter, durch viren vermittelter dna-transfer
EP1757703A3 (de) Self-inaktivierender Gammaretrovirenvektor
ATE256196T1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
DE60042816D1 (de) T-helferzellen-epitope
DE59807012D1 (de) Flip-gen und flip-protein
DE60233756D1 (de) Vektorvermittelte organellentransfektion
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
ATE335075T1 (de) L-aminosäure-oxidase aus rhodococcus-arten
AU4903099A (en) Targeted integration into chromosomes using retroviral vectors
ZA200404424B (en) Genes encoding for genetic stability, gene expression and folding proteins.
NO20030962L (no) Gener som koder for polypeptider fra methylomonas s.p. involvert i eksopolysakkaridproduksjon
DE60210970D1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
AU2001240078A1 (en) Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
DE69834813D1 (de) Parvovirus-Vektoren und deren Verwendung
DE60125773D1 (de) Cds1-knockout-mäusen und davon abgeleitete zelllinien
DK1442054T3 (da) Aequorin som et reportergen i gær

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1282712

Country of ref document: EP